{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:05:52Z","timestamp":1782536752771,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T00:00:00Z","timestamp":1531526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["702491"],"award-info":[{"award-number":["702491"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["705290"],"award-info":[{"award-number":["705290"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jconrel.2018.07.025","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T09:55:28Z","timestamp":1531907728000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor"],"prefix":"10.1016","volume":"286","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-1248","authenticated-orcid":false,"given":"Ada W.Y.","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malathi","family":"Anantha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wieslawa H.","family":"Dragowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Wehbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel B.","family":"Bally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.07.025_bb0005","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1074\/jbc.M112.411611","article-title":"Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription","volume":"288","author":"Andrews","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrc1015","article-title":"Does the ribosome translate cancer?","volume":"3","author":"Ruggero","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev.pharmtox.010909.105844","article-title":"The RNA polymerase I transcription machinery: an emerging target for the treatment of Cancer","volume":"50","author":"Drygin","year":"2010","journal-title":"Annu. Rev. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.bbagrm.2012.10.014","article-title":"Dysregulation of RNA polymerase I transcription during disease","volume":"1829","author":"Hannan","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.20347","article-title":"Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma","volume":"45","author":"Williamson","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrm1551","article-title":"RNA polymerases I and III, growth control and cancer","volume":"6","author":"White","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2867-14-18","article-title":"The basal transcription machinery as a target for cancer therapy","volume":"14","author":"Villicana","year":"2014","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nm.4291","article-title":"A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress","volume":"23","author":"Bruno","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0050","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.drudis.2013.08.012","article-title":"Targeting the nucleolus for cancer-specific activation of p53","volume":"19","author":"Drygin","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0060","article-title":"CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours","volume":"8","author":"Xu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0065","doi-asserted-by":"crossref","unstructured":"A. Khot, N. Brajanovski, D. Cameron, N. Hein, G.A. McArthur, J.K.C. Lim, S.E. O'Brien, D. Ryckman, G.I. Yu, E. Link, C. Donohoe, A. Snowden, R. Hannan, S.J. Harrison, A Phase 1, Open-label, dose escalation, safety, pharmacokinetic and pharmacodynamic study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced haematologic malignancies (HM), Clin. Lymp. Myeloma Leukemia, 15 e280-e281.","DOI":"10.1016\/j.clml.2015.07.578"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0070","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1182\/blood.V122.21.3941.3941","article-title":"Inhibition of RNA polymerase I transcription by CX-5461 as a therapeutic strategy for the Cancer-specific activation of p53 in highly refractory Haematological malignancies","volume":"122","author":"O'Brien","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0075","doi-asserted-by":"crossref","unstructured":"M. Haddach, M.K. Schwaebe, J. Michaux, J. Nagasawa, S.E. O'Brien, J.P. Whitten, F. Pierre, P. Kerdoncuff, L. Darjania, R. Stansfield, D. Drygin, K. Anderes, C. Proffitt, J. Bliesath, A. Siddiqui-Jain, M. Omori, N. Huser, W.G. Rice, D.M. Ryckman, Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for Cancer Therapeutics, ACS Medi. Chem. Lett., 3 (2012) 602\u2013606.","DOI":"10.1021\/ml300110s"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0378-5173(02)00704-4","article-title":"An intravenous formulation decision tree for discovery compound formulation development","volume":"253","author":"Lee","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","article-title":"Inhibition of RNA polymerase I as a therapeutic strategy to promote Cancer-specific activation of p53","volume":"22","author":"Bywater","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0090","first-page":"76","article-title":"A novel formulation of CX-5461, a small-molecule inhibitor of rRNA synthesis, and its use for treatment of acute myeloid leukemia models","author":"Leung","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-4889(87)90047-4","article-title":"Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages","volume":"931","author":"Derksen","year":"1987","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Mol. Cell Res."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0100","first-page":"827","article-title":"The severe combined immunodeficient (Scid) mouse as a model for human myeloid Leukemias","volume":"7","author":"Cesano","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0105","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1182\/blood-2006-06-029579","article-title":"ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia","volume":"109","author":"Shankar","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153416","article-title":"Nanoscale reaction vessels designed for synthesis of copper-drug complexes suitable for preclinical development","volume":"11","author":"Wehbe","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0115","doi-asserted-by":"crossref","first-page":"10758","DOI":"10.1039\/C7DT01955F","article-title":"A perspective - can copper complexes be developed as a novel class of therapeutics?","volume":"46","author":"Wehbe","year":"2017","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149516","article-title":"Mechanism of copper uptake from blood plasma Ceruloplasmin by mammalian cells","volume":"11","author":"Ramos","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0125","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0130","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.2147\/IJN.S137347","article-title":"Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent","volume":"12","author":"Wehbe","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0135","series-title":"Veterinary Toxicology","first-page":"425","article-title":"Chapter 26 - Copper A2 - Gupta","author":"Thompson","year":"2018"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1508\/cytologia.65.235","article-title":"Potential genotoxicity in copper Sulphate treated mice","volume":"65","author":"Fahmy","year":"2000","journal-title":"CYTOLOGIA"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0145","series-title":"Parenteral Copper Sulfate Poisoning Causing Acute Renal Failure, Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association","first-page":"441","volume":"vol. 14","author":"Oldenquist","year":"1999"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0304-4165(83)90223-4","article-title":"Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen","volume":"761","author":"Patel","year":"1983","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0155","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1039\/C5MT00149H","article-title":"Targeting copper in cancer therapy: 'Copper that Cancer'","volume":"7","author":"Denoyer","year":"2015","journal-title":"Metallomics"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/DDDT.S119488","article-title":"Metal complexes in cancer therapy \u2013 an update from drug design perspective","volume":"11","author":"Ndagi","year":"2017","journal-title":"Drug Design Dev. Ther."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0165","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing Cytarabine and Daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/2278-330X.149950","article-title":"Novel formulation of cytarabine and daunorubicin: a new hope in AML treatment","volume":"4","author":"Raut","year":"2015","journal-title":"South Asian J. Cancer"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0175","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy048.003","article-title":"44OCCTG IND.231: a phase 1 trial evaluating CX-5461 in patients with advanced solid tumors","volume":"29","author":"Hilton","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0180","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-07-0780","article-title":"Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors","volume":"14","author":"Ramsay","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002800050846","article-title":"Preclinical pharmacology, toxicology and efficacy of sphingomyelin\/cholesterol liposomal vincristine for therapeutic treatment of cancer","volume":"42","author":"Webb","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0190","doi-asserted-by":"crossref","first-page":"34846","DOI":"10.18632\/oncotarget.5413","article-title":"Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells","volume":"6","author":"Negi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jnci\/59.1.221","article-title":"One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice","volume":"59","author":"Fogh","year":"1977","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0200","first-page":"250","article-title":"Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics","volume":"106","author":"Kyriazis","year":"1982","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","article-title":"Phenotype and genotype of pancreatic cancer cell lines","volume":"39","author":"Deer","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0210","first-page":"175","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0215","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1538-7445.AM2014-2735","article-title":"Abstract 2735: multi-point targeting of the synthetic lethal interactions between Myc, ribosome biogenesis and ribosome function cooperates to treat B-cell lymphoma","volume":"74","author":"Pearson","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0220","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/MCB.00589-10","article-title":"Distinguishing the roles of topoisomerases I and II in relief of transcription-induced torsional stress in yeast rRNA genes","volume":"31","author":"French","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0225","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1128\/MCB.17.4.1787","article-title":"A34.5, a nonessential component of yeast RNA polymerase I, cooperates with subunit A14 and DNA topoisomerase I to produce a functional rRNA synthesis machine","volume":"17","author":"Gadal","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0230","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0012-1606(77)90180-4","article-title":"Isolation of ribosomal gene chromatin","volume":"55","author":"Higashinakagawa","year":"1977","journal-title":"Dev. Biol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0235","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1101\/gad.6.7.1332","article-title":"Topoisomerases and yeast rRNA transcription: negative supercoiling stimulates initiation and topoisomerase activity is required for elongation","volume":"6","author":"Schultz","year":"1992","journal-title":"Genes Dev."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"127","author":"Stein","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0245","first-page":"1","article-title":"Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials, Wiley interdisciplinary reviews","volume":"9","author":"Caster","year":"2016","journal-title":"Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2018.07.025_bb0250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/pbc.25133","article-title":"Efficacy of CPX-351,(cytarabine: daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program","volume":"62","author":"Carol","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2018.07.025_bb0255","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591830419X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591830419X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:34:38Z","timestamp":1759160078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591830419X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":51,"alternative-id":["S016836591830419X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.07.025","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}